» Articles » PMID: 8892925

An in Vivo Mutation from Leucine to Tryptophan at Position 210 in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Contributes to High-level Resistance to 3'-azido-3'-deoxythymidine

Overview
Journal J Virol
Date 1996 Nov 1
PMID 8892925
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Sequencing of the reverse transcriptase (RT) region of 26 human immunodeficiency virus type 1 (HIV-1) isolates from eight patients treated with 3'-azido-3'-deoxythymidine (AZT) revealed a mutation at codon 210 from TTG (leucine) to TGG (tryptophan) exclusively in association with resistance to AZT. The mutation Trp-210 was observed in 15 of the 20 isolates phenotypically resistant to AZT, being more commonly observed than resistance-associated mutations at codons 67, 70, and 219. Trp-210 was never observed before the emergence of resistance-associated mutations Leu-41 and Tyr-215, and in a sequential series of five isolates from one patient the order of emergence of mutations was found to be Tyr-215, Leu-41, and then Trp-210. Trp-210 was also found in association with the Leu-41, Asn-67, Arg-70, and Tyr-215 resistance genotype. To define the role of Trp-210 in AZT resistance, molecular HIV-1 clones were constructed with various combinations of RT mutations at codons 41, 67, 70, 210, and 215 and tested for susceptibility to AZT. In clones with polymerase genes derived either from HXB2-D or clinical isolates, Trp-210 alone did not increase AZT resistance, whereas in conjunction with Leu-41 and Tyr-215, Trp-210 contributed to high-level resistance (50% inhibitory concentration of >1 microM). In HXB2-D, Trp-210 with Tyr-215 generated a virus with resistance comparable to one with Leu-41, Tyr-215, and Trp-210. Inserting Trp-210 into the genetic context of mutations at codons 41, 67, 70, and 215 further enhanced resistance from a 50% inhibitory concentration of 1.44 microM to 8.41 microM. Molecular modeling of the tertiary structure of HIV-1 RT revealed that the distance between the side chains of Trp-210 (in helix alphaF) and Tyr-215 (in strand beta11a) approximated 4 A (1 A = 0.1 nm), sufficiently close to result in significant energetic interaction between these two aromatic side chains. In conclusion, Trp-210 contributes significantly to phenotypic AZT resistance of HIV-1 by augmenting resistance at least three- to sixfold in the context of two resistant genotypes, and its effect may require an interaction with an aromatic amino acid at position 215.

Citing Articles

Avoiding Drug Resistance in HIV Reverse Transcriptase.

Cilento M, Kirby K, Sarafianos S Chem Rev. 2021; 121(6):3271-3296.

PMID: 33507067 PMC: 8149104. DOI: 10.1021/acs.chemrev.0c00967.


Therapy of HIV Infection: Current Approaches and Prospects.

Prokofjeva M, Kochetkov S, Prassolov V Acta Naturae. 2017; 8(4):23-32.

PMID: 28050264 PMC: 5199204.


Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.

Schneider A, Corona A, Sporing I, Jordan M, Buchholz B, Maccioni E Nucleic Acids Res. 2016; 44(5):2310-22.

PMID: 26850643 PMC: 4797301. DOI: 10.1093/nar/gkw060.


Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.

Boyer P, Das K, Arnold E, Hughes S Antimicrob Agents Chemother. 2015; 59(12):7184-96.

PMID: 26324274 PMC: 4649230. DOI: 10.1128/AAC.05069-14.


Silent mutations at codons 65 and 66 in reverse transcriptase alleviate indel formation and restore fitness in subtype B HIV-1 containing D67N and K70R drug resistance mutations.

Telwatte S, Hearps A, Johnson A, Latham C, Moore K, Agius P Nucleic Acids Res. 2015; 43(6):3256-71.

PMID: 25765644 PMC: 4381058. DOI: 10.1093/nar/gkv128.


References
1.
Kozal M, Shafer R, Winters M, Katzenstein D, Merigan T . A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis. 1993; 167(3):526-32. DOI: 10.1093/infdis/167.3.526. View

2.
van Leeuwen R, Lange J, Hussey E, Donn K, Hall S, Harker A . The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study. AIDS. 1992; 6(12):1471-5. DOI: 10.1097/00002030-199212000-00008. View

3.
Tisdale M, Kemp S, Parry N, Larder B . Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci U S A. 1993; 90(12):5653-6. PMC: 46779. DOI: 10.1073/pnas.90.12.5653. View

4.
Ding J, Nanni R, Clark Jr A, Lu X, Tantillo C, Williams R . Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. Proc Natl Acad Sci U S A. 1993; 90(13):6320-4. PMC: 46920. DOI: 10.1073/pnas.90.13.6320. View

5.
Eron J, Chow Y, Caliendo A, Videler J, Devore K, Cooley T . pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob Agents Chemother. 1993; 37(7):1480-7. PMC: 187998. DOI: 10.1128/AAC.37.7.1480. View